title: A randomized phase II study of acivicin and 4'deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study.
abstract: We analyzed 56 of 75 previously untreated patients with hepatocellular carcinoma who entered on a prospectively randomized trial of acivicin versus 4'deoxydoxorubicin (esorubicin). At least one episode of severe toxicity was documented in 23% of the patients on acivicin and 45% of those on 4'deoxydoxorubicin. Two patients responded to 4'deoxydoxorubicin. One response was partial, lasting 58 weeks, and one was complete, lasting more than 4 years. The 90% confidence interval for response is 1-20%. In view of a 45% rate of severe or worse toxicity with 4'deoxydoxorubicin, this drug cannot be recommended as treatment. There were no responses on acivicin.
authors.affiliation: Department of Medical Oncology, University of Pretoria, Republic of South Africa.
authors.forename: G
authors.initials: G
authors.lastname: Falkson
authors.forename: A
authors.initials: A
authors.lastname: Cnaan
authors.forename: I W
authors.initials: IW
authors.lastname: Simson
authors.forename: Y
authors.initials: Y
authors.lastname: Dayal
authors.forename: H
authors.initials: H
authors.lastname: Falkson
authors.forename: T J
authors.initials: TJ
authors.lastname: Smith
authors.forename: D G
authors.initials: DG
authors.lastname: Haller
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D000903:Antibiotics, Antineoplastic; D007555:Isoxazoles; D004317:Doxorubicin; C006303:acivicin; C030851:esorubicin